Literature DB >> 11829322

Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus?

J Widimský1, B Strauch, G Sindelka, J Skrha.   

Abstract

Aldosterone-producing adenoma (aldosteronoma)--the most frequent form of primary hyperaldosteronism (PH)--is considered a specific form of diabetes mellitus (DM). In a previous study we demonstrated insulin resistance in patients with PH. We have therefore undertaken a study to evaluate the incidence of abnormalities of glucose metabolism in patients with PH (36 subjects) compared to control subjects with essential hypertension (EH) (21 patients). The following parameters were measured in all studied subjects: office blood pressure (by mercury sphygmomanometer in the sitting position), body mass index (BMI), plasma potassium, plasma glucose and insulin levels during oral glucose tolerance test (OGTT) (0, 60, 120 min), plasma renin activity and plasma aldosterone. Although patients with PH tended to have higher stimulated plasma glucose levels after 60 and 120 min compared to EH, these differences did not attain statistical significance. Patients with EH tended to have higher insulin levels at each measured interval, but due to a high variability these differences were again not significant. There were no significant differences between PH and EH in the proportion of diabetics (20% vs. 14%) or patients with impaired glucose tolerance (18% vs. 10%). In conclusion, we have found the absence of significant differences in the frequency of diabetes mellitus, impaired glucose tolerance and insulin resistance in patients with EH and PH. Our data thus do not support the idea of primary hyperaldosteronism as a specific type of diabetes mellitus. Furthermore, our results indicate that glucose metabolic characteristics in essential hypertension and primary hyperaldosteronism tend to be similar. The definitive conclusion with respect to the possible causal relationship between DM and PH, however, can be obtained only on larger groups of subjects, in particular after the evaluation of the effect of surgical/pharmacological treatment of primary hyperaldosteronism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11829322

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  14 in total

Review 1.  Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis.

Authors:  W Chen; F Li; C He; Y Zhu; W Tan
Journal:  Ir J Med Sci       Date:  2013-08-30       Impact factor: 1.568

Review 2.  Aldosterone and cardiovascular risk.

Authors:  Bruno Vogt; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

Review 3.  Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease.

Authors:  Guanghong Jia; Warren Lockette; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-01-13       Impact factor: 3.619

4.  Worsening of lipid metabolism after successful treatment of primary aldosteronism.

Authors:  Christian Adolf; Evelyn Asbach; Anna Stephanie Dietz; Katharina Lang; Stefanie Hahner; Marcus Quinkler; Lars Christian Rump; Martin Bidlingmaier; Marcus Treitl; Roland Ladurner; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

Review 5.  The effect of aldosterone on glucose metabolism.

Authors:  Dalila B Corry; Michael L Tuck
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 6.  The metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Giovanni Federspil; Franco Veglio; Paolo Mulatero
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

Review 7.  Effects of aldosterone on insulin sensitivity and secretion.

Authors:  James M Luther
Journal:  Steroids       Date:  2014-09-04       Impact factor: 2.668

8.  Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism.

Authors:  Shivraj Grewal; Andin Fosam; Liam Chalk; Arjun Deven; Mari Suzuki; Ricardo Rafael Correa; Jenny E Blau; Andrew Paul Demidowich; Constantine A Stratakis; Ranganath Muniyappa
Journal:  Endocrine       Date:  2021-01-18       Impact factor: 3.633

9.  Visceral adipose tissue: emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterations.

Authors:  Marco Boscaro; Gilberta Giacchetti; Vanessa Ronconi
Journal:  Ann N Y Acad Sci       Date:  2012-07-17       Impact factor: 5.691

Review 10.  The metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Giovanni Federspil; Franco Veglio; Paolo Mulatero
Journal:  Curr Hypertens Rep       Date:  2007-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.